论文部分内容阅读
作者自1989年2月以来应用HD－DAE（DDP100mg～120mg／m2第1天静滴；ADM40mg／m2第1天静注；VP－16100mg第1～5天静滴）方案治疗晚期肺癌，可评价者232例，每个病例经1～6周期，平均1．3周期化疗，疗效达CR24例（10．3％），PR173例（74．6％），有效缓解率84．9％。在CR病例中有7例在行支气管镜复查时细胞学或／和病理学为阴性，另有24例在化疗后得以行肺切除手术，其中3例手术标本病灶及转移淋巴结仅见癌细胞残形，失去细胞结构。经6年观察现本组病例中位缓解期14个月，中位生存期18个月。1年生存率84．1％，2年生存率68．1％，3年生存率46．6％，4年生存率10．3％，5年生存率0．86％。其毒性反应达Ⅲ、Ⅳ期者在胃肠道15．5％，肾脏2．6％，骨髓造血系统25．9％，其中与化疗有关死亡3例（1．3％）。实践证明本方案对晚期肺癌具有较高的临床缓解率，使生存期得以显著延长，是晚期肺癌有效的联合化疗方案。作者还对方案中各抗癌药协同合作机制进行了分析。
Since February 1989, the authors have applied HD-DAE (DDP 100mg ~ 120mg/m2 on the first day of intravenous infusion; ADM40mg/m2 on the first day of intravenous injection; VP-16100mg on the first to 5th days of intravenous infusion) regimen for the treatment of advanced lung cancer, can be evaluated Among 232 patients, each case was treated with 1 to 6 cycles, with an average of 1.3 cycles of chemotherapy. The efficacy was CR 24 cases (10.3%), PR 173 cases (74.6%), and the effective remission rate was 84.9%. In CR cases, 7 cases were cytological or/and pathologically negative at the time of bronchoscopic review, and another 24 cases were able to undergo lung resection after chemotherapy. Among them, only 3 cases of surgical specimens and metastatic lymph nodes showed only cancerous remnants. , lose cell structure. After 6 years of observation, the median remission period of the current group of patients was 14 months, and the median survival period was 18 months. The 1-year survival rate was 84.1%, the 2-year survival rate was 68.1%, the 3-year survival rate was 46.6%, the 4-year survival rate was 10.3%, and the 5-year survival rate was 0.86%. The toxicity of the patients in stage III and IV was 15.5% in the gastrointestinal tract, 2.6% in the kidney, and 25.9% in the bone marrow hematopoietic system, among which 3 deaths (1.3%) were related to chemotherapy. The practice has proved that this program has a higher clinical remission rate for advanced lung cancer and significantly prolongs the survival period. It is an effective combination chemotherapy for advanced lung cancer. The authors also analyzed the synergy mechanism of each cancer drug in the protocol.